What is the exit plan (acquisition, IPO, merger, etc.) in which investors will be able to see a ROI?

Our plan has always been exit by acquisition.

Is there evidence to support this technology? Is it FDA-approved? Is it patented? Are you currently working with any practices, hospitals, or hospital systems? Please answer those questions for me.

There are many research studies that demonstrate cooling prevents CIPN. It's becoming more and more widely accepted and clinics are struggling, trying to get their patients to cool. Unfortunately, there isn't a safe and easy way to do it, to meet the unique needs of cancer patients. Until now. We do not need FDA approval and will launch as 510(k) exempt. Yes, we have three patents filed. Oncologists and nurses have told us they don't have the resources to purchase and manage the devices and w...

Hi Carole, A few questions if you can answer : 1. Paxman is developing a cryocompression device for the same CIPN indication - FDA 510(k) under review, CPT codes already established, trials at SWOG/Dana-Farber, and an existing 600–900+ site infusion-center footprint. Do you ha...

1. We are thrilled that Paxman also recognizes the importance of this problem! Our goal is to end CIPN so the more smart people working on it, the better. That said, there are several differences between our approach and Paxman's. Our device is portable and meant to go home with the patient, to give the optimal cooling time (we know it takes hours for the drug to clear in the blood). Also we've designed our gloves and booties so patients can "live" in them - they can use their hands and safel...

Hi Carole, I have a few questions 1. For the pivotal clinical study supporting the CIPN indication, what endpoints do you expect to measure, approximately how many patients will be required, and when do you expect to have a decision-quality efficacy readout? 2. Beyond the init...

Hi Johnathon,Great questions. We just submitted an SBIR grant application to run a small feasibility study which will give us more precise answers to your questions about a larger, efficacy study. We are looking at patients getting grade 2 or higher peripheral neuropathy. Remember that this is not needed to go to market but we are doing this in parallel to our market launch as a 510(k) exempt device.On the reimbursement question, we will pursue a new HCPCS code because our device is in-clinic...

Hey Carole,, Thanks for the detailed response. A few remaining points would help complete my diligence: 1. For the planned feasibility and larger efficacy studies, what endpoints, sample size and success thresholds are you currently considering, and when would you expect a dec...

Hi Johnathon, These are great questions and really hit upon confidential information that i do not feel I can share on this public forum. Please reach out to me at carole@eisanahealth.com. Thanks!

Eisana Health

Reducing permanent nerve damage from chemotherapy

eisanahealth.com

The Woodlands, TX

Technology B2B Healthcare Hardware B2C

What Investors Say

LEAD INVESTOR

Invested $25,000 this round

I am very excited to be an investor in Eisana Health because of their potential to help hundreds of thousands of cancer patients live a better life after treatment. Eisana Health is uniquely poised to revolutionize cancer care by helping patients prevent the permanent and painful nerve damage that common chemotherapy drugs cause. This is a unique opportunity to directly invest in a company that could spare you or a loved one from a permanent disability in the future.

What People Say

Eisana Health

Quick facts

Team profiles

$289,561

What Investors Say